Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept in MDS/MPN-RS-T and MDS/MPN-U with RS
NCT05005182Phase 2Terminated
- Sponsor
- Mayo Clinic
- Start
- Feb 2023
- Primary completion
- Apr 2023
- Countries
- 1
01
Overview
A Phase 2 trial of luspatercept in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T), myelodysplastic/myeloproliferative neoplasm (MDS/MPN), sponsored by Mayo Clinic. Started Feb 2023; status: terminated.
02
Drugs
luspatercept
03
Conditions
myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)
Beyond the preview
Go deeper on NCT05005182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05005182.